C83.26 Mixed small and large cell (diffuse) non-Hodgkin's lymphoma, intrapelvic lymph nodes

Name of the Condition

• Mixed small and large cell (diffuse) non-Hodgkin's lymphoma, intrapelvic lymph nodes
• Also known as ICD-10 code C83.26

Summary

Mixed small and large cell (diffuse) non-Hodgkin's lymphoma is a subtype of non-Hodgkin lymphoma characterized by the malignant proliferation of both small and large lymphoid cells in a diffuse pattern. It typically involves abnormal growth of B-cells or T-cells in the intrapelvic lymph nodes, without forming follicular structures. This condition is part of the broader category of non-follicular lymphomas and may present with variable clinical behavior depending on the specific cell composition and distribution.

Causes

The exact cause of mixed small and large cell (diffuse) non-Hodgkin's lymphoma remains unknown. It is thought to involve genetic mutations or abnormalities in lymphoid cell development, though specific triggers are not well-defined. Research suggests potential links to immune system dysregulation or prior infections, but no definitive etiology has been established.

Risk Factors

• Age: More common in older adults.
• Family history of lymphoma.
• Prior exposure to radiation or certain chemicals.
• Chronic infections, such as hepatitis C or HIV.
• Immunosuppressive conditions or treatments.

Symptoms

• Swollen, painless lymph nodes in the pelvic region.
• Unexplained weight loss.
• Fever.
• Night sweats.
• Fatigue.
• Abdominal or pelvic discomfort.

Diagnosis

Diagnosis typically involves a combination of physical examination, imaging studies (e.g., CT or MRI of the pelvis), and biopsy of the affected lymph nodes. Histopathological analysis confirms the presence of mixed small and large cell morphology in a diffuse pattern. Additional tests, such as flow cytometry or immunohistochemistry, may be used to identify cell type (B-cell or T-cell) and rule out other conditions. Staging studies, including PET scans, help determine the extent of disease.

Treatment Options

Treatment depends on the stage, cell type, and patient health. Options may include chemotherapy, immunotherapy, targeted therapy, or radiation therapy. In some cases, a combination of these approaches is used. Clinical trials or specialized protocols may be considered for advanced or refractory disease.

Prognosis and Follow-Up

Prognosis varies based on factors like stage, cell type, and response to treatment. Regular follow-up with imaging and clinical assessments is essential to monitor for recurrence or progression. Long-term surveillance may be recommended, especially if the disease is in remission.

Complications

Potential complications include disease progression, treatment-related side effects (e.g., infection risk from immunosuppression), organ involvement, or transformation to a more aggressive lymphoma subtype.

Lifestyle & Prevention

While prevention is not fully established, maintaining a healthy immune system through balanced nutrition, regular exercise, and avoiding known risk factors (e.g., excessive radiation exposure) may support overall health. Prompt treatment of chronic infections is advisable.

When to Seek Professional Help

Seek medical attention for persistent pelvic swelling, unexplained weight loss, fever, or other systemic symptoms. Early evaluation is critical for timely diagnosis and management.

Tips for Medical Coders

Use code C83.26 for documentation of mixed small and large cell (diffuse) non-Hodgkin's lymphoma specifically involving intrapelvic lymph nodes. Ensure clinical documentation specifies the anatomical site (intrapelvic) and histological subtype to support accurate coding. Review pathology reports and imaging findings to confirm the diagnosis and site.